Holen Sie sich die Stockscreener-App
1.77
2.92%
0.06
Fibrobiologics Inc Aktie (FBLG) Neueste Nachrichten
Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications - ACCESS Newswire
FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing - finance.yahoo.com
FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media - Morningstar
A new patent covers a way to promote repair in damaged spinal discs from FibroBiologics. - Stock Titan
FibroBiologics ships new batch of diabetic ulce... - Pluang
FibroBiologics ships third batch of trial drug to Australia - Investing.com
FibroBiologics ships third batch of trial drug to Australia By Investing.com - Investing.com India
FibroBiologics ships a third batch of wound treatment being tested to Australia - Stock Titan
FibroBiologics regains Nasdaq bid price compliance - Investing.com
FibroBiologics Adds Sports Agent Leigh Steinberg to Board of Directors - citybiz
FibroBiologics appoints Leigh Steinberg to board By Investing.com - Investing.com Canada
Leigh Steinberg, agent behind $4B in deals, joins FibroBiologics (FBLG) board - Stock Titan
FibroBiologics appoints Leigh Steinberg to board - Investing.com
FibroBiologics | 10-Q: Q1 2026 Earnings Report - Moomoo
FibroBiologics receives Australian patent for disc disease therapy By Investing.com - Investing.com Canada
FibroBiologics receives Australian patent for disc disease therapy - Investing.com
FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease - Morningstar
FibroBiologics Says Preclinical Data Shapes Design of Further Studies for Degenerative Joint Treatment - Sahm
FibroBiologics reports cartilage repair in animal study By Investing.com - Investing.com South Africa
FibroBiologics reports cartilage repair in animal study - Investing.com
Animal joints showed cartilage repair within four weeks of one injection - Stock Titan
Armistice Capital discloses 9.99% FibroBiologics (FBLG) stake via Master Fund - Stock Titan
FibroBiologics Inc - Smartkarma
FBLG Q2 2026 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Biotech Advances Fibroblast Pipeline - vinanet.vn
FBLG Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 7.77% Share GainEarnings Surprise Stocks - vinanet.vn
FibroBiologics receives patent for islet transplant method By Investing.com - Investing.com UK
FibroBiologics receives patent for islet transplant method - Investing.com
Fibrobiologics Granted US Patent Covering The Use Of Fibroblasts - TradingView
FibroBiologics Patent Could Help Stretch Scarce Donor Pancreases - Stock Titan
FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets - PR Newswire
FibroBiologics (FBLG) Holds at $0.98 as Biotech Stock Tests Key Trading RangeFibonacci Extension - vinanet.vn
Fibrobiologics Inc (FBLG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FBLG Q2 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesRevenue Report - vinanet.vn
Fibrobiologics Inc (FBLG) Stock News Today - TradingKey
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage - marketscreener.com
FibroBiologics patent covers Sox9 turning fibroblasts into cartilage cells - Stock Titan
H.C. Wainwright cuts FibroBiologics price target to $6 on model adjustments - Investing.com
FibroBiologics Faces Material Clinical Trial and Regulatory Risks That Threaten Commercialization Timeline and Long-Term Outlook - TipRanks
FibroBiologics, Inc. Revenue Breakdown – NASDAQ:FBLG - TradingView
FBLG: Advanced clinical pipeline, reduced R&D costs, raised $12M, and expanded patent assets - tradingview.com
FibroBiologics Q2 EPS beats estimates as losses narrow 72.5% - scanx.trade
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate - PR Newswire
FIBROBIOLOGICS ($FBLG) Releases Q2 2026 Earnings - Quiver Quantitative
FibroBiologics, Inc. 2Q 2026: Net loss $(4.12M), EPS $(0.66) — 10-Q Summary - TradingView
FibroBiologics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Form DEF 14A FIBROBIOLOGICS For: 31 July By Investing.com - Investing.com Nigeria
FBLG Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Stage ContinuesEarnings Decline Risk - vinanet.vn
FBLG Q1 2026 Earnings: EPS Misses Slightly as Pre‑Revenue Biotech Continues R&D FocusForward EPS Estimate - vinanet.vn
Fibrobiologics Inc (FBLG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fibrobiologics Inc (FBLG) Earnings Date & Reports & Earnings News - TradingKey
Fibrobiologics Inc (FBLG) Valuation: PE, PB & Fair Value Analysis - TradingKey
FBLG|Fibrobiologics Inc|Price:0.681|Chg%:-0.031 - TradingKey
Fibrobiologics Inc (FBLG) Institutional Confidence - TradingKey
0.28%
4.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):